BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28591517)

  • 1. An ATP-Responsive Codelivery System of Doxorubicin and MiR-34a To Synergistically Inhibit Cell Proliferation and Migration.
    Wang Y; Chen J; Liang X; Han H; Wang H; Yang Y; Li Q
    Mol Pharm; 2017 Jul; 14(7):2323-2332. PubMed ID: 28591517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cell proliferation through an ATP-responsive co-delivery system of doxorubicin and Bcl-2 siRNA.
    Zhang J; Wang Y; Chen J; Liang X; Han H; Yang Y; Li Q; Wang Y
    Int J Nanomedicine; 2017; 12():4721-4732. PubMed ID: 28740380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual ATP/reduction-responsive polyplex to achieve the co-delivery of doxorubicin and miR-23b for the cancer treatment.
    Tang X; Liang X; Wen K; Chen Y; Han H; Li Q
    Colloids Surf B Biointerfaces; 2021 Oct; 206():111955. PubMed ID: 34216852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymeric Hybrid Nanomicelles for Cancer Theranostics: An Efficient and Precise Anticancer Strategy for the Codelivery of Doxorubicin/miR-34a and Magnetic Resonance Imaging.
    Xie X; Chen Y; Chen Z; Feng Y; Wang J; Li T; Li S; Qin X; Wu C; Zheng C; Zhu J; You F; Liu Y; Yang H
    ACS Appl Mater Interfaces; 2019 Nov; 11(47):43865-43878. PubMed ID: 31684723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cell proliferation and migration by chondroitin sulfate-g-polyethylenimine-mediated miR-34a delivery.
    Liang S; Duan Y; Xing Z; Han H; Zhang A; Li L; Yang Y; Li Q
    Colloids Surf B Biointerfaces; 2015 Dec; 136():577-84. PubMed ID: 26454548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoic Acid-Modified Oligoethyleneimine-Mediated miR-34a Delivery to Achieve the Anti-Tumor Efficacy.
    Huang Y; Wang L; Chen Y; Han H; Li Q
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy.
    Yao C; Liu J; Wu X; Tai Z; Gao Y; Zhu Q; Li J; Zhang L; Hu C; Gu F; Gao J; Gao S
    J Control Release; 2016 Jun; 232():203-14. PubMed ID: 27126903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way.
    Xie J; Liu JH; Liu H; Liao XZ; Chen Y; Lin MG; Gu YY; Liu TL; Wang DM; Ge H; Mo SL
    BMC Cancer; 2016 Nov; 16(1):899. PubMed ID: 27863471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-34a inhibits oral cancer progression partially by repression of interleukin-6-receptor.
    Li T; Li L; Li D; Wang S; Sun J
    Int J Clin Exp Pathol; 2015; 8(2):1364-73. PubMed ID: 25973020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination treatment with doxorubicin and microRNA-21 inhibitor synergistically augments anticancer activity through upregulation of tumor suppressing genes.
    Zhang S; Han L; Wei J; Shi Z; Pu P; Zhang J; Yuan X; Kang C
    Int J Oncol; 2015 Apr; 46(4):1589-600. PubMed ID: 25625875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chondroitin sulfate-functionalized polyamidoamine as a tumor-targeted carrier for miR-34a delivery.
    Chen W; Liu Y; Liang X; Huang Y; Li Q
    Acta Biomater; 2017 Jul; 57():238-250. PubMed ID: 28511876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-335 directly, while miR-34a indirectly modulate survivin expression and regulate growth, apoptosis, and invasion of gastric cancer cells.
    Yang B; Huang J; Liu H; Guo W; Li G
    Tumour Biol; 2016 Feb; 37(2):1771-9. PubMed ID: 26318298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleobase-modified polyamidoamine-mediated miR-23b delivery to inhibit the proliferation and migration of lung cancer.
    Han H; Yang J; Wang Y; Chen W; Chen J; Yang Y; Li Q
    Biomater Sci; 2017 Oct; 5(11):2268-2275. PubMed ID: 28976503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Potassium Pentagamavunon-0 and Doxorubicin Induces Apoptosis and Cell Cycle Arrest and Inhibits Metastasis in Breast Cancer Cells.
    Putri H; Jenie RI; Handayani S; Kastian RF; Meiyanto E
    Asian Pac J Cancer Prev; 2016; 17(5):2683-8. PubMed ID: 27268651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Near Infrared-Guided Smart Nanocarriers for MicroRNA-Controlled Release of Doxorubicin/siRNA with Intracellular ATP as Fuel.
    Zhang P; Wang C; Zhao J; Xiao A; Shen Q; Li L; Li J; Zhang J; Min Q; Chen J; Chen HY; Zhu JJ
    ACS Nano; 2016 Mar; 10(3):3637-47. PubMed ID: 26905935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the Intracellular Drug Concentration in Lung Cancer Treatment through the Codelivery of Doxorubicin and miR-519c Mediated by Porous PLGA Microparticle.
    Wu D; Wang C; Yang J; Wang H; Han H; Zhang A; Yang Y; Li Q
    Mol Pharm; 2016 Nov; 13(11):3925-3933. PubMed ID: 27684197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential combinational effect of miR-34a with celecoxib in osteosarcoma.
    Chen X; Peng D; Shen Y; Liu B; Zhou H; Tao H; Huang J
    Anticancer Drugs; 2017 Sep; 28(8):888-897. PubMed ID: 28650862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue.
    Salzano G; Costa DF; Sarisozen C; Luther E; Mattheolabakis G; Dhargalkar PP; Torchilin VP
    Small; 2016 Sep; 12(35):4837-4848. PubMed ID: 27432595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells.
    Tazawa H; Tsuchiya N; Izumiya M; Nakagama H
    Proc Natl Acad Sci U S A; 2007 Sep; 104(39):15472-7. PubMed ID: 17875987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.